| Lindsey J Beck, DO | |
|
2900 12th Ave N Ste 140w, Billings, MT 59101-7507 | |
| (406) 237-5050 | |
| (406) 238-6599 |
| Full Name | Lindsey J Beck |
|---|---|
| Gender | Female |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 12 Years |
| Location | 2900 12th Ave N Ste 140w, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043570880 | NPI | - | NPPES |
| 68128 | Other | MT | LICENSE |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Missoula Bone And Joint, Llc | 3870583990 | 46 |
News Archive
Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.
Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
› Verified 2 days ago
| Entity Name | Ortho Montana, Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174515878 PECOS PAC ID: 5193627404 Enrollment ID: O20040126000480 |
News Archive
Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.
Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
› Verified 2 days ago
| Entity Name | Missoula Bone & Joint, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447207212 PECOS PAC ID: 3870583990 Enrollment ID: O20040512001126 |
News Archive
Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.
Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsey J Beck, DO 2900 12th Ave N Ste 140w, Billings, MT 59101-7507 Ph: (406) 237-5050 | Lindsey J Beck, DO 2900 12th Ave N Ste 140w, Billings, MT 59101-7507 Ph: (406) 237-5050 |
News Archive
Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.
Vivaglobin (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies.
Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
› Verified 2 days ago
Blackshear Morrison Bryan, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1233 N 30th St, Billings, MT 59101 Phone: 406-237-7125 Fax: 406-237-7190 | |
Dr. Gregg L Singer, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 1643 Lewis Ave, Suite 7, Billings, MT 59102 Phone: 406-655-0980 Fax: 406-294-0967 | |
Lynn F. Shenk, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Jeffrey Smith, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1520 24th St W, Billings, MT 59102 Phone: 834-040-6318 | |
Michael Henry Schabacker, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N, Suite 335w, Billings, MT 59101 Phone: 406-237-8808 Fax: 406-238-6151 | |
Josiah Engebretson, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2900 12th Ave N Ste 140w, Billings, MT 59101 Phone: 406-237-5050 Fax: 406-272-3395 | |
Terrence J Cahill, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |